Podcast Episodes
Back to Search
From sequence to scale: Gene editing’s new era in biologics manufacturing
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We…
an hour ago
Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil
A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhil…
2 days, 8 hours ago
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
The vibe at BIO 2026 in San Diego last week was overwhelmingly positive, with attendees observing noticeable changes at the FDA and an uptick in deal…
1 week, 2 days ago
The Golden Triangle and the gaps: Rethinking UK biotech
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll hear from Hakan Goker, managing direct…
2 weeks, 1 day ago
AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more
This year has been partly defined by a return to M&A. In the first quarter of 2026, biopharma spent nearly $47 billion in acquisitions across 19 deal…
2 weeks, 2 days ago
From fragile skin to living medicine: Lessons from RDEB
In this episode of Denatured, you'll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therap…
3 weeks, 1 day ago
Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more
Moderna’s mRNA-based flu vaccine made headlines in February when the FDA declined to even review the application. Days later, the agency reversed cou…
3 weeks, 2 days ago
Portugal, Spain and the new biotech frontier
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll hear from Hannah Franklin, associate …
4 weeks, 1 day ago
Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence
Everything came up roses for Eli Lilly at the American Diabetes Association, as the pharma boasted positive results for its new pill Foundayo and nex…
1 month ago
Rethinking hair loss treatment
In this episode of Denatured, you'll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of …
1 month ago